Supplemental Blood Test Bridges Breast Cancer Screening Gaps
- A novel blood test, Certitude Breast, is being developed to provide an accessible screening option for women lacking easy access to traditional mammography, notably in rural areas.
- Over 10% of counties in the United states have either zero or only one mammogram facility,impacting access for over 10 million women. This disparity highlights the need for...
- A case-controlled study involving 300 women is in press, and a presentation at the San Antonio Breast Cancer Symposium showcased data from a biobank of 1250 women, demonstrating...
“`html
Certitude Breast: A New Blood Test Aims to Improve Breast cancer Screening Access
Table of Contents
A novel blood test, Certitude Breast, is being developed to provide an accessible screening option for women lacking easy access to traditional mammography, notably in rural areas. The test is positioned as a non-imaging option potentially comparable to MRI in detecting breast cancer.
the Challenge of Breast Cancer Screening Access
Over 10% of counties in the United states have either zero or only one mammogram facility,impacting access for over 10 million women. This disparity highlights the need for alternative screening methods, especially in underserved areas. Certitude Breast aims to address this gap by offering a convenient blood test as an initial screening tool.
Certitude Breast: Performance and Validation
Early data from Certitude Breast show promising results. A case-controlled study involving 300 women is in press, and a presentation at the San Antonio Breast Cancer Symposium showcased data from a biobank of 1250 women, demonstrating high sensitivity and specificity. These initial findings suggest the test can accurately identify potential cancer indicators.
According to justin Drake, Ph.D., the next steps involve rigorous prospective trials.These trials will compare the blood testS performance against established methods like MRI and contrast-enhanced mammography. A pre-biopsy study is also planned, focusing on differentiating between benign and cancerous lesions to reduce unnecessary biopsies.
Upcoming Clinical Trials and Regulatory Pathways
Certitude Breast is currently undergoing validation through several prospective trials in collaboration with leading medical institutions:
- Mayo Clinic: Comparison of Certitude Breast to MRI.
- University of Pittsburgh Medical Center: Comparison of Certitude Breast to contrast-enhanced mammography.
- Pre-Biopsy Study: Evaluation of the test’s ability to rule out benign lesions and minimize unnecessary biopsies.
These trials are crucial for generating real-world evidence and establishing the clinical utility of Certitude Breast. Successful completion of these studies will be a key step towards potential regulatory approval and integration into annual screening programs.
Understanding Sensitivity and Specificity
In the context of medical testing, sensitivity refers to the test’s ability to correctly identify individuals *with* the disease (true positive rate), while specificity measures its ability to correctly identify individuals *without* the disease (true negative rate). High sensitivity and specificity are both crucial for an effective screening test. A highly sensitive test minimizes false negatives, while a highly specific test minimizes